Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Video Interview: Nabriva Plans Second Phase III Trial

This article was originally published in Scrip

Executive Summary

Having raised just over $90m in an IPO on NASDAQ last year, Nabriva Therapeutics will invest some $80m on two international Phase III trials of its lead pleuromutilin product candidate, lefamulin, to treat community-acquired bacterial pneumonia (CABP). Nabriva CEO Colin Broom tells Mike Ward, Informa Pharma Insights global director of content, the company is poised to start its second trial in 740 patients which he expects to complete in mid-2017.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC064461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel